Sotyktu

Sotyktu (deucravacitinib) treats psoriasis by selectively targeting the immune system by inhibiting tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family. Sotyktu is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

What is Sotyktu?

How Is It Used?

Sotyktu is taken once-daily by mouth.

What are the most common adverse reactions?

The most common adverse reactions (≥1%) are upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.

Three men near a car, one sitting in the driver seat with the door open.

FDA Approves Sotyktu™ for Psoriasis

A new oral treatment option for adults with plaque psoriasis.

Read Article

Psoriasis 101

Newly diagnosed? Want a refresher? Dr. Jason E. Hawkes is here to break down the science of psoriatic disease.

Learn More

A smiling doctor hands her patient a prescription in an office.

Provider Directory

Find the health care provider that is right for you.

Read Article

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today